Toll-like receptor agonists and alpha-galactosylceramide synergistically enhance the production of interferon-gamma in murine splenocytes

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Ando, Tatsuya ^a   Ito, Hiroyasu ^a   Ohtaki, Hirofumi ^a   Seishima, Mitsuru ^a  

^a GIFU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; ALPHA-GALACTOSYLCERAMIDE; GALACTOSYLCERAMIDE; GAMMA INTERFERON; TOLL LIKE RECEPTOR;

ANIMAL; ARTICLE; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DRUG EFFECT; DRUG POTENTIATION; MALE; METABOLISM; MOUSE; PHYSIOLOGY; SIGNAL TRANSDUCTION; SPLEEN; AGONISTS; DRUG EFFECTS;

ANIMALS; CELLS, CULTURED; DRUG SYNERGISM; GALACTOSYLCERAMIDES; INTERFERON-GAMMA; MALE; MICE; MICE, INBRED C57BL; SIGNAL TRANSDUCTION; SPLEEN; TOLL-LIKE RECEPTORS;

EID: 84884199048     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep02559     Document Type: Article

References (32)

1. Kronenberg, M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 23, 877-900 (2005). (Pubitemid 40563188)
2. Taniguchi, M., Harada, M., Kojo, S., Nakayama, T. & Wakao, H. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 21, 483-513 (2003). (Pubitemid 37174539)
3. Mattarollo, S. R. et al. NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. Blood 120, 3019-3029 (2012).
4. Reilly, E. C. et al. Activated iNKT cells promote memory CD81 T cell differentiation during viral infection. PLoS One 7, e37991 (2012).
5. Qian, G. et al. High doses of alpha-galactosylceramide potentiate experimental autoimmune encephalomyelitis by directly enhancing Th17 response. Cell Res 20, 480-491 (2010).
6. Ito, H. et al. Role of Valpha141 NKT cells in the development of Hepatitis B virus-specific CTL: activation of Valpha141 NKT cells promotes the breakage of CTL tolerance. Int Immunol 20, 869-879 (2008). (Pubitemid 351865862)
7. Ito, H. et al. Lethal endotoxic shock using alpha-galactosylceramide sensitization as a new experimental model of septic shock. Lab Invest 86, 254-261 (2006). (Pubitemid 43276957)
8. Ito, H. et al. Augmentation of lipopolysaccharide-induced nitric oxide production by alpha-galactosylceramide in mouse peritoneal cells. J Endotoxin Res 11, 213-219 (2005).
9. Ohtaki, H. et al. Valpha14 NKT cells activated by alpha- galactosylceramide augment lipopolysaccharide-induced nitric oxide production in mouse intrahepatic lymphocytes. Biochemical and biophysical research communications 378, 579-583 (2009).
10. Schmieg, J., Yang, G., Franck, R. W. & Tsuji, M. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide. The Journal of experimental medicine 198, 1631-1641 (2003). (Pubitemid 37494156)
11. Ohtaki, H. et al. High susceptibility to lipopolysaccharide-induced lethal shock in encephalomyocarditis virus-infected mice. Sci Rep 2, 367 (2012).
12. Ingram, J. T., Yi, J. S. & Zajac, A. J. Exhausted CD8 T cells downregulate the IL-18 receptor and become unresponsive to inflammatory cytokines and bacterial coinfections. PLoS Pathog 7, e1002273 (2011).
13. Souza-Fonseca-Guimaraes, F., Adib-Conquy, M. & Cavaillon, J. M. Natural killer (NK) cells in antibacterial innate immunity: angels or devils Mol Med 18, 270-285 (2012).
14. Rossato, M. et al. IL-10-induced microRNA-187 negatively regulates TNF-alpha, IL-6, and IL-12p40 production in TLR4-stimulated monocytes. Proceedings of the National Academy of Sciences of the United States of America 109, E3101-3110 (2012).
15. Fujimoto, K. et al. A new subset of CD1031CD8alpha1 dendritic cells in the small intestine expresses TLR3, TLR7, and TLR9 and induces Th1 response and CTL activity. J Immunol 186, 6287-6295 (2011).
16. Schroder, K., Hertzog, P. J., Ravasi, T. & Hume, D. A. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75, 163-189 (2004). (Pubitemid 38174573)
17. Zaidi, M. R. & Merlino, G. The two faces of interferon-gamma in cancer. Clin Cancer Res 17, 6118-6124 (2011).
18. Steinhagen, F., Kinjo, T., Bode, C. & Klinman, D. M. TLR-based immune adjuvants. Vaccine 29, 3341-3355 (2011).
19. Wolska, A., Lech-Maranda, E. & Robak, T. Toll-like receptors and their role in hematologic malignancies. Curr Mol Med 9, 324-335 (2009).
20. Stahl-Hennig, C. et al. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog 5, e1000373 (2009).
21. Boland, G. et al. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 23, 316-320 (2004). (Pubitemid 39463048)
22. Paavonen, J. et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374, 301-314 (2009).
23. Sondak, V. K. et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 20, 2058-2066 (2002). (Pubitemid 34408796)
24. Vantomme, V. et al. Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J Immunother 27, 124-135 (2004). (Pubitemid 38282732)
25. Wille-Reece, U.,Wu, C. Y., Flynn, B. J., Kedl, R. M. & Seder, R. A. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD81 T cell responses. J Immunol 174, 7676-7683 (2005). (Pubitemid 40806272)
26. Adams, S. et al. Immunization of malignant melanoma patients with fulllength NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 181, 776-784 (2008).
27. Feyerabend, S. et al. Novel multi-peptide vaccination in Hla-A21 hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 69, 917-927 (2009).
28. Halperin, S. A. et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 24, 20-26 (2006). (Pubitemid 41721097)
29. Speiser, D. E. et al. Rapid and strong human CD81T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115, 739-746 (2005). (Pubitemid 40322250)
30. Veldt, B. J. et al. Randomized placebo controlled phase I/II trial of alphagalactosylceramide for the treatment of chronic hepatitis C. JHepatol 47, 356-365 (2007). (Pubitemid 47176162)
31. Fujii, S. et al. Adjuvant activity mediated by iNKT cells. Semin Immunol 22, 97-102 (2010).
32. Woltman, A. M. et al. Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial. Antivir Ther 14, 809-818 (2009).